Our story
2012
2013
2014
2015
2019
2021
2022
2023
Creation of the IRT
3 employees + 3 volunteers
13 projects
Structure: 13 technical platforms and 6 technology centers
61 employees
Structure: Paris 600m2 (offices and labs) / Lyon 820m2 (offices and labs)
Teams spread over 6 locations in Lyon (Lyonbiopole, ANSES, IN2P3, Accinov and ISA) and at Institut Pasteur
86 employees
15 projects
New structure: 7 technological units and 4 thematic units
100 employees
Moving into the new building in Lyon with 2,200m2 of laboratories and 1,360m2 of offices, in addition to the 850m2 premises in Paris.
31 projects
Structure: 7 technological units + 1: Bioassays, Microsystems and Optical Engineering
4 programs: Antimicrobials, Diagnostic, Microbiome, Vaccines
110 employees
BIOASTER celebrated its 10th anniversary!
To create together...
Founders
0
Co-founding leaders
0
Funding supports
0
Public research institutions
0
Major of healthcare industry
The ecosystem
BIOASTER is an actor in or member of various networks that aim to facilitate the application of technological innovation in the health sector.
BIOASTER is at the heart of the health ecosystem in France. This positioning allows the Institute to provide its partners with knowledge of the networks that exist in the sector, both to identify and engage the most appropriate players in a project and to promote new synergies and complementarity that benefit all the parties concerned.
ecosystem
ecosys-
tem
tem
eco-
sys-
tem
sys-
tem
Support networks for innovation and technology transfer: FIT, competitiveness clusters, and SATT
FIT association
BIOASTER, as an IRT, is a member of the FIT association, the “French Institute of Technology”, which was created in 2014. The FIT association brings together 15 institutes that were created as part of the Future Investments Program (PIA) and share the same fundamental principles regarding public-private multi-partner research. Within the FIT association, IRTs and ITEs are strengthening their ties and maximizing their competencies, with the aim of identifying home-grown, sustainable, and resilient technological innovations that accelerate environmental, digital, and societal transitions in our territories.
Competitiveness cluster
BIOASTER is a member of the LyonBiopôle competitiveness cluster. The LyonBiopôle represents an innovative and fertile health ecosystem with international connections within the Auvergne-Rhône-Alpes region.
BIOASTER has been part of this global competitiveness cluster since its creation in 2005. It supports projects and companies in the sector and aims to aid the development of technological innovations, products, and services to meet the health challenges of tomorrow.
BIOASTER has been part of this global competitiveness cluster since its creation in 2005. It supports projects and companies in the sector and aims to aid the development of technological innovations, products, and services to meet the health challenges of tomorrow.
SATT network
More broadly, BIOASTER communicates and collaborates on a case-by-case basis with other SATTs (Technology Transfer Acceleration Companies). BIOASTER performs studies at the request of a SATT or provides observations regarding the maturity of the technologies supported by SATTs.
SATT Pulsalys
BIOASTER and Pulsalys signed a memorandum of understanding in 2017. This cooperation agreement aims to combine the complementary expertise of the two partners. BIOASTER and PULSALYS agreed to:
- undertake discussions in order to identify opportunities for joint projects, and in particular projects in which BIOASTER would validate, and if appropriate, disseminate technologies developed by PULSALYS
- consider access for BIOASTER to the services offered by PULSALYS, in particular with respect to intellectual property management.
- discuss best practices regarding innovation, technology transfer, and the protection of research findings.
Thematic initiatives: Hub VPH, TWB, and APM
Hub VPH
BIOASTER is one of the founding partners of the HUB VPH (Veterinary Public Health). The HUB VPH (Veterinary Public Health) is an unprecedented public-private initiative that involves nine major players in the health ecosystem in the Auvergne-Rhône-Alpes region.
This first Veterinary Public Health hub was created on the basis of a common desire: to become a world-class reference center for Veterinary Public Health, and was driven by the strong collaborative tradition in the Auvergne-Rhône-Alpes region and recognition of the importance of addressing international Veterinary Public Health issues.
This first Veterinary Public Health hub was created on the basis of a common desire: to become a world-class reference center for Veterinary Public Health, and was driven by the strong collaborative tradition in the Auvergne-Rhône-Alpes region and recognition of the importance of addressing international Veterinary Public Health issues.
TWB
BIOASTER is a member of the Toulouse White Biotechnology (TWB) consortium. TWB provides concrete assistance for companies and biotechnology entrepreneurs in the development of products and processes using bio-sourced raw materials, from the laboratory to the pre-industrial pilot stage. As a member of the Strategic Orientation Committee, BIOASTER contributes to the definition of TWB’s roadmap and to the annual selection of self-financed public research projects, using its knowledge and vision regarding biotechnology and technological tools.
APM
BIOASTER is one of the founders of the Alliance Promotion Microbiote (APM). The APM was instigated not only to consolidate the existing ecosystem, but also to develop it, strengthen it, and accelerate the deployment of potential approaches to address the key challenges of attractiveness, national interest, health independence, and access to innovative therapies in France.
BEAM
As an associate member of the Biotech companies in Europe combating AntiMicrobial Resistance (BEAM) alliance, BIOASTER contributes to the federation of European initiatives to tackle antimicrobial resistance. BIOASTER’s relationships with some of the SME participants in the BEAM alliance manifest as joint research projects, such as DACCAR with Da Volterra and PhagUTI with Pherecydes Pharma.
Cynbiome
Cynbiome® is a preclinical network dedicated to research into the microbiome that aims to capitalize on the richness and complementarity of players specializing in fields such as high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, and preclinical and clinical activities.
Cynbiome® undertakes preclinical R&D activities, focusing on the microbiome and infectious diseases.
BIOASTER is a player in the development of innovative technologies for healthcare purposes, bringing its expertise, means, and resources to the pursuit of these objectives, and is an enthusiastic participant in the partnership and collaborative approaches to the development of common objectives and projects.
Cynbiome® undertakes preclinical R&D activities, focusing on the microbiome and infectious diseases.
BIOASTER is a player in the development of innovative technologies for healthcare purposes, bringing its expertise, means, and resources to the pursuit of these objectives, and is an enthusiastic participant in the partnership and collaborative approaches to the development of common objectives and projects.
Pharmabiotic Research Institute
The PRI was founded to make Microbial Medicinal Products a therapeutic reality in Europe. The PRI believes that the microbiome represents the future of human medicine. The members have stakes in the regulatory, technical, and collaborative efforts regarding the microbiome and human health space. Dr Vincent Thomas, Head of the Microbiota Program at BIOASTER, is a PRI Board Member.